U.S. company Halozyme Therapeutics, regarded as a competitor to Korea's bio corporations Alteogen, will acquire Elektrofi, which has subcutaneous injection drug delivery technology, for up to $900 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback